Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Japanese shares slide as investors flee risk on pandemic uncertainty

Published 04/24/2020, 11:17 AM
Updated 04/24/2020, 11:20 AM

TOKYO, April 24 (Reuters) - Japanese shares edged down on
Friday, as their rebound since last month showed signs of
fatigue, with investors still in the dark over when and how
quickly the economy can recover from the fallout of the
coronavirus pandemic.
Cyclical shares led the losses, with 29 of 33 industry
sub-indexes in the Tokyo Stock Exchange trading in the red,
while semiconductor-related shares were hit by dim earnings
outlook from U.S. chipmaker Intel INTC.O .
The Nikkei share average .N225 fell 0.81% to 19,272.42. It
held above its 25-day moving average, now at 18,969 but faces
resistance from 50-day average at 19,894.
The market is on track for its first weekly loss in three,
with the Nikkei down 3.1% by midday.
The broader Topix .TOPX lost 0.62% on Friday morning to
1,417.21.
Semi-conductor shares were bruised by a 6% drop in Intel
INTC.O shares in extended trade after the chipmaker forecast
second-quarter earnings below Wall Street views, but said it was
unclear about its annual outlook due to the economic uncertainty
caused by the pandemic. Disco 6146. fell 3.5% even as the semi-conductor
manufacturing machine maker announced consensus-beating earnings
for Jan-March the previous session.
Advantest 6857.T lost 2.1%, while Tokyo Electron 8035.T
fell 1.9%.
Corporate earnings from Japanese companies have started to
trickle in, but provided little clarity so far on what to expect
from the rest of the season.
Canon Inc 7751.T shed 2.8% after the camera and copy
machine maker withdrew earnings forecast for the current
financial year, citing difficulty in predicting the end of the
coronavirus impact.
Its net profit in the Jan-March quarter dropped 30% from a
year earlier, though it came in better than market expectations.
Bucking the trend, Omron 6645.T rose 5.1% after its
full-year profit topped estimates. Chugai Pharmaceutical 4519.T gained 2.6% as the drugmaker
reported brisk profit growth in the quarter that ended in March.


Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.